tetano
Editor, Senior Moderator
BMJ Open
. 2025 Nov 5;15(11):e110210.
doi: 10.1136/bmjopen-2025-110210. Aspirin to prevent cardiovascular events in patients with community-acquired pneumonia or influenza (ASCAP study): protocol for a multicentre, randomised, double-blind, placebo-controlled trial
Vahram Hovsepjan[SUP] 1 2 [/SUP], Abel Thijs[SUP] 3 4 [/SUP], Jeske J K van Diemen[SUP] 3 4 [/SUP], Johannes A Bogaards[SUP] 5 6 [/SUP], Michiel M Winter[SUP] 7 [/SUP], Judith E Bosmans[SUP] 6 8 [/SUP], Jan M Prins[SUP] 3 [/SUP]; ASCAP study group
Collaborators, Affiliations
Introduction: Cardiovascular events (CVEs), in particular acute coronary syndrome (ACS), complicate the course of a significant number of patients hospitalised for community-acquired pneumonia (CAP) or influenza. Emerging evidence suggests that this increased risk of CVEs could be mitigated by the use of acetylsalicylic acid (aspirin). The ASCAP study investigates whether the addition of aspirin to standard therapy in hospitalised patients with moderate-to-severe CAP or influenza can reduce the incidence of CVEs.
Methods and analysis: The ASCAP study is a multicentre, double-blind, placebo-controlled randomised trial in 16 university and general hospitals in the Netherlands, in which patients are randomised to acetylsalicylic acid or matching placebo for 90 days. Eligible patients are adults hospitalised for moderate-to-severe CAP or influenza. Patients with antithrombotic or anticoagulant drugs, or those with contraindications for aspirin, are excluded. The primary outcome is the incidence of ACS up to day 180. Secondary outcomes include the incidence of 4-point major adverse cardiovascular events up to day 180, as well as the incidence of major bleeding and clinically relevant non-major bleeding events up to day 90, all-cause mortality up to day 180 and quality of life and societal costs up to day 180. Survival time will be analysed by the log-rank test, stratified for CAP and influenza, with a two-sided alpha of 0.05. Assuming an average baseline ACS risk of 7.5% over 180 days with up to 30% variation across strata, and a 60% hazard reduction due to aspirin, the required sample size to achieve 80% power is 760 patients. Currently, 114 patients are enrolled in the study.
Ethics and dissemination: This study is approved by the Medical Ethics Committee Amsterdam UMC (Amsterdam, The Netherlands) under reference number 2023.0741 and registered under EU trial number 2023-504553-12-01 in the EU portal CTIS (Clinical Trials Information System). Results of the study will be published in a peer-reviewed journal.
Trial registration number: EU CTIS: 2023-504553-12-01.
Keywords: Cardiovascular Disease; INFECTIOUS DISEASES; Myocardial infarction; Randomized Controlled Trial; Respiratory infections.
. 2025 Nov 5;15(11):e110210.
doi: 10.1136/bmjopen-2025-110210. Aspirin to prevent cardiovascular events in patients with community-acquired pneumonia or influenza (ASCAP study): protocol for a multicentre, randomised, double-blind, placebo-controlled trial
Vahram Hovsepjan[SUP] 1 2 [/SUP], Abel Thijs[SUP] 3 4 [/SUP], Jeske J K van Diemen[SUP] 3 4 [/SUP], Johannes A Bogaards[SUP] 5 6 [/SUP], Michiel M Winter[SUP] 7 [/SUP], Judith E Bosmans[SUP] 6 8 [/SUP], Jan M Prins[SUP] 3 [/SUP]; ASCAP study group
Collaborators, Affiliations
- PMID: 41198196
- DOI: 10.1136/bmjopen-2025-110210
Introduction: Cardiovascular events (CVEs), in particular acute coronary syndrome (ACS), complicate the course of a significant number of patients hospitalised for community-acquired pneumonia (CAP) or influenza. Emerging evidence suggests that this increased risk of CVEs could be mitigated by the use of acetylsalicylic acid (aspirin). The ASCAP study investigates whether the addition of aspirin to standard therapy in hospitalised patients with moderate-to-severe CAP or influenza can reduce the incidence of CVEs.
Methods and analysis: The ASCAP study is a multicentre, double-blind, placebo-controlled randomised trial in 16 university and general hospitals in the Netherlands, in which patients are randomised to acetylsalicylic acid or matching placebo for 90 days. Eligible patients are adults hospitalised for moderate-to-severe CAP or influenza. Patients with antithrombotic or anticoagulant drugs, or those with contraindications for aspirin, are excluded. The primary outcome is the incidence of ACS up to day 180. Secondary outcomes include the incidence of 4-point major adverse cardiovascular events up to day 180, as well as the incidence of major bleeding and clinically relevant non-major bleeding events up to day 90, all-cause mortality up to day 180 and quality of life and societal costs up to day 180. Survival time will be analysed by the log-rank test, stratified for CAP and influenza, with a two-sided alpha of 0.05. Assuming an average baseline ACS risk of 7.5% over 180 days with up to 30% variation across strata, and a 60% hazard reduction due to aspirin, the required sample size to achieve 80% power is 760 patients. Currently, 114 patients are enrolled in the study.
Ethics and dissemination: This study is approved by the Medical Ethics Committee Amsterdam UMC (Amsterdam, The Netherlands) under reference number 2023.0741 and registered under EU trial number 2023-504553-12-01 in the EU portal CTIS (Clinical Trials Information System). Results of the study will be published in a peer-reviewed journal.
Trial registration number: EU CTIS: 2023-504553-12-01.
Keywords: Cardiovascular Disease; INFECTIOUS DISEASES; Myocardial infarction; Randomized Controlled Trial; Respiratory infections.